Out-of-Specification ORS: Retesting, Release and a Repeated Failure
A PPB-accredited quality control laboratory tests a batch of low-osmolarity oral rehydration salts (20.5 g sachets) from a local manufacturer. The sodium assay gives 82.5% of label claim against a 90.0-110.0% specification; chloride is also low. The analyst retests the same sample in duplicate before any documented laboratory investigation and obtains 84.1% and 83.7%, both failing. The QC manager suggests 'a third retest; if it passes, release it'. The batch is 180,000 sachets, of which 60,000 have already gone to 14 counties. The manufacturer's annual product review shows this is the third out-of-specification result for sodium this year; the two earlier batches were released after retests. The laboratory's SOP allows a maximum of two retests but is silent on what to do when a retest fails, and there is no written Phase I investigation record.
1. Was the retesting valid? What should the QC manager do now?
Read the worked answer
The retesting was not valid. An out-of-specification result must trigger a documented Phase I laboratory investigation - analyst, method, instrument, standards, sample handling, calculation - before any retest. Retesting without that record is testing into compliance. The two retests already performed confirm the failure rather than overturning it; a third retest chosen because it might pass has no scientific basis and would be a data-integrity finding on inspection.
The manager should: open a formal OOS investigation with a hypothesis and root cause (sodium chloride or citrate content of raw materials, weighing, mixing uniformity, fill weight, moisture), preserve all original data and chromatograms, retain the failed samples, and issue a CAPA. The SOP must be revised to define Phase I and Phase II investigations and to state explicitly that retesting is permitted only when the investigation identifies an assignable laboratory cause, never to obtain a passing result.
Do not release the batch. The result is a confirmed OOS, and the earlier released batches now look suspect because they were released on the same invalid basis.
2. What is the batch disposition and market action, including for the 60,000 sachets already distributed?
Read the worked answer
Reject the batch. Notify the PPB, then initiate a recall of the distributed stock - Class II is the reasonable starting point, because subpotent ORS risks inadequate rehydration, particularly in children with diarrhoea, but does not usually carry an immediate life-threatening probability at the point of use. Escalate to Class I if the shortfall is clinically significant at the dilution actually used.
Market actions. Trace the 60,000 sachets to the 14 counties, notify the facilities, retrieve stock, and arrange replacement. Record quantities distributed, recovered and destroyed.
Look backwards. Re-examine the two earlier batches released after retests. If their release rested on the same invalid practice, assess retained samples and recall them too.
Escalate systemically. A third OOS in a year is a pattern, not an accident: trigger a GMP inspection focused on the manufacturer's OOS and CAPA systems, consider suspension of the product line or a variation requirement, and review the QC laboratory's accreditation given its SOP gap. Communicate with clinicians and the public only through approved channels, with a clear statement of what to use instead.